Implementation strategies for depression and anxiety screening in a pediatric cystic fibrosis center: A quality improvement project.


Journal

Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590

Informations de publication

Date de publication:
12 2020
Historique:
received: 13 12 2019
accepted: 07 07 2020
pubmed: 10 7 2020
medline: 18 3 2021
entrez: 10 7 2020
Statut: ppublish

Résumé

Guidelines to integrate mental health screening (MHS) into Cystic fibrosis (CF) care has increased adoption across the United States and European CF Centers, however, there has been limited discussion on specific strategies for implementation. Share key strategies that led to successful MHS implementation in one pediatric CF center and report implementation and screening outcomes. Parent partners, mental health experts from the Department of Psychiatry, and the CF clinic team codesigned interventions to support three major stakeholders: (a) patients and families (b) clinic team, and (c) hospital system. The mental health coordinator approached patients (12 and older) to introduce MHS and administered screening and reviewed results using an electronic tablet and digital measurement-feedback system. We used strategies that promoted visibility of screening progress and sharing of data with hospital administration. Descriptive statistics were used to assess prevalence of clinically significant symptoms of anxiety and depression and symptom severity within our sample. Over the first 2 years of the project, we exceeded our goal of screening 80% of eligible patients per year (80%-95% screened) and are on a similar trajectory within the first 7 months of year 3. We identified high prevalence of clinically significant symptoms of depression (16%) and anxiety (14%) similar to those found in other chronic illness populations. These data helped us advocate hospital leadership to support the development of new mental health services to address identified needs at our center. Leveraging coproduction to address stakeholder needs led to successful implementation of a sustainable MHS process.

Sections du résumé

BACKGROUND
Guidelines to integrate mental health screening (MHS) into Cystic fibrosis (CF) care has increased adoption across the United States and European CF Centers, however, there has been limited discussion on specific strategies for implementation.
OBJECTIVE
Share key strategies that led to successful MHS implementation in one pediatric CF center and report implementation and screening outcomes.
METHODS
Parent partners, mental health experts from the Department of Psychiatry, and the CF clinic team codesigned interventions to support three major stakeholders: (a) patients and families (b) clinic team, and (c) hospital system. The mental health coordinator approached patients (12 and older) to introduce MHS and administered screening and reviewed results using an electronic tablet and digital measurement-feedback system. We used strategies that promoted visibility of screening progress and sharing of data with hospital administration. Descriptive statistics were used to assess prevalence of clinically significant symptoms of anxiety and depression and symptom severity within our sample.
RESULTS
Over the first 2 years of the project, we exceeded our goal of screening 80% of eligible patients per year (80%-95% screened) and are on a similar trajectory within the first 7 months of year 3. We identified high prevalence of clinically significant symptoms of depression (16%) and anxiety (14%) similar to those found in other chronic illness populations. These data helped us advocate hospital leadership to support the development of new mental health services to address identified needs at our center.
CONCLUSION
Leveraging coproduction to address stakeholder needs led to successful implementation of a sustainable MHS process.

Identifiants

pubmed: 32644305
doi: 10.1002/ppul.24951
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

3328-3336

Subventions

Organisme : AHRQ HHS
ID : K12 HS026393
Pays : United States

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Iturralde E, Adams RN, Barley RC, et al. Implementation of depression screening and global health assessment in pediatric subspecialty clinics. J Adolesc Health. 2017;61(5):591-598.
Quittner AL, Goldbeck L, Abbott J, et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. Thorax. 2014;69(12):1090-1097.
Riekert KA, Bartlett SJ, Boyle MP, Krishnan JA, Rand CS. The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis. Chest. 2007;132(1):231-237.
Gundogdu U, Fis NP, Eralp EE, Karadag BT. Major depression and psychiatric comorbidity in Turkish children and adolescents with cystic fibrosis. Pediatr Pulmonol. 2019;54(12):1927-1935.
Snell C, Fernandes S, Bujoreanu IS, Garcia G. Depression, illness severity, and healthcare utilization in cystic fibrosis. Pediatr Pulmonol. 2014;49(12):1177-1181.
Quittner AL, Abbott J, Georgiopoulos AM, et al. International committee on mental health in cystic fibrosis: cystic fibrosis foundation and European cystic fibrosis society consensus statements for screening and treating depression and anxiety. Thorax. 2016;71(1):26-34.
Zuckerbrot RA, Cheung A, Jensen PS, Stein RE, Laraque D, GLAD-PC STEERING GROUP. Guidelines for adolescent depression in primary care (GLAD-PC): part I. Practice preparation, identification, assessment, and initial management. Pediatrics. 2018;141(3):1-21.
Abbott J, Havermans T, Jarvholm S, et al. ECFS Mental Health Working Group. Mental health screening in cystic fibrosis centres across Europe. J Cyst Fibros. 2019;18(2):299-303.
Garcia G, Snell C, Sawicki G, Simons LE. Mental health screening of medically-admitted patients with cystic fibrosis. Psychosomatics. 2018;59:158-168.
Smith BA, Georgiopoulos AM, Quittner AL. Maintaining mental health and function for the long run in cystic fibrosis. Pediatr Pulmonol. 2016;51:S71-S78.
Institute for Healthcare Improvement. Key Driver Diagram. Retrieved from http://www.ihi.org/resources/Pages/Tools/Driver-Diagram.aspx on 5/31/2020.
Nandakumar AL, Vande Voort JL, Nakonezny PA, et al. Psychometric properties of the patient health questionnaire-9 modified for major depressive disorder in adolescents. J Child Adolesc Psychopharmacol. 2019;29(1):34-40.
Liu FF, Adrian MC. Is treatment working? detecting real change in the treatment of child and adolescent depression. J Am Acad Child Adolesc Psychiatry. 2019;58(12):1157-1164.
Cannon DS, Tiffany ST, Coon H, Scholand MB, McMahon WM, Leppert MF. The PHQ-9 as a brief assessment of lifetime major depression. Psychol Assess. 2007;19(2):247-251.
Löwe B, Decker O, Müller S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care. 2008;46:266-274.
Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychistry. 2016;39:24-31.
Mossman SA, Luft MJ, Schroeder HK, et al. The Generalized Anxiety Disorder 7-item (GAD-7) scale in adolescents with generalized anxiety disorder: signal detection and validation. Ann Clin Psychiatry. 2017;29(4):227-234.
Zemanick ET, Daines CL, Dellon EP, et al. Highlights from the 2016 North American cystic fibrosis conference. Pediatr Pulmonol. 2017;52(8):1103-1110.
Harris SK. Making time for mental health: computerized previsit screening in primary care. J Adolesc Health. 2015;56(3):257-258.
Dudeney J, Sharpe L, Jaffe A, Jones EB, Hunt C. Anxiety in youth with asthma: a meta-analysis. Pediatr Pulmonol. 2017;52(9):1121-1129.
Riekert KA, Bartlett SJ, Boyle MP, Krishnan JA, Rand CS. The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis. Chest. 2007;132(1):231-237.
Cystic Fibrosis Foundation. 2018. Cystic Fibrosis Mental Health Change Package. [cited 2019 Sep 17]. Available from: http://app.ihi.org/FacultyDocuments/Events/Event-3135/Posterboard-6847/Document-6587/IHI_Poster_CFF_MH_Change_Package_10012018_submitted.pdf

Auteurs

Freda F Liu (FF)

Child and Adolescent Division, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington.
Cystic Fibrosis Center, Seattle Children's Hospital, Seattle, Washington.

Al Lew (A)

Cystic Fibrosis Center, Seattle Children's Hospital, Seattle, Washington.

Elizabeth Andes (E)

Cystic Fibrosis Center, Seattle Children's Hospital, Seattle, Washington.

Sharon McNamara (S)

Cystic Fibrosis Center, Seattle Children's Hospital, Seattle, Washington.

Janine Cassidy (J)

Cystic Fibrosis Center, Seattle Children's Hospital, Seattle, Washington.

Susan Whitmore (S)

Cystic Fibrosis Center, Seattle Children's Hospital, Seattle, Washington.

Rich Plunkett (R)

Cystic Fibrosis Center, Seattle Children's Hospital, Seattle, Washington.

Thida Ong (T)

Cystic Fibrosis Center, Seattle Children's Hospital, Seattle, Washington.
Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH